Compare BCPC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | LEGN |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.9B |
| IPO Year | 1995 | 2020 |
| Metric | BCPC | LEGN |
|---|---|---|
| Price | $171.61 | $21.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $176.00 | $61.33 |
| AVG Volume (30 Days) | 128.9K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ 20.87 | N/A |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $799,023,000.00 | N/A |
| Revenue This Year | $8.47 | $42.68 |
| Revenue Next Year | $4.89 | $30.52 |
| P/E Ratio | $65.65 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $139.17 | $16.24 |
| 52 Week High | $183.90 | $37.50 |
| Indicator | BCPC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 51.95 |
| Support Level | $159.54 | $20.70 |
| Resistance Level | $176.62 | $21.97 |
| Average True Range (ATR) | 3.48 | 1.00 |
| MACD | -1.17 | 0.24 |
| Stochastic Oscillator | 5.09 | 57.84 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.